✦ LIBER ✦

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

✍ Scribed by C.E.M. Hollack; R. Goudsmith; M. Ek; A.E.R.Kr. von dem Borne; M.H.J. van Oers; J.M.F.G. Aerts; S. van Meely; S.S.K.S. Phoa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

36. Dose–response relationships for enzy

✍ Gregory Grabowski; K. Kacena; C.E.M. Hollak; L. Zhang; J. Yee; P. Mistry; A. Zim 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Replacement therapy with imiglucerase fo

✍ A. Zimran; D. Elstein; E. Levy-Lahad; S. Zevin; I. Hadas-Halpern; A. Abrahamov; 📂 Article 📅 1995 🏛 The Lancet 🌐 English ⚖ 251 KB

Low-Dose N-Butyldeoxynojirimycin (OGT 91

✍ Rene Heitner; Deborah Elstein; Johannes Aerts; Sonja van Weely; Ari Zimran 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Enzyme replacement therapy in type 1 and

✍ Ari Zimran; Deborah Elstein; Ayalah Abrahamov 📂 Article 📅 1995 🏛 The Lancet 🌐 English ⚖ 335 KB

No justification for very high-dose enzy

✍ Ari Zimran; Deborah Elstein 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 174 KB

Individualized long-term enzyme therapy

✍ Majda Benedik-Dolničar; Lidija Kitanovski 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB